[Effects of bradykinin in the cardiovascular effects of angiotensin-converting enzyme inhibitors].
The role of bradykinin in the cardiovascular effects of angiotensin converting enzyme inhibitors remains difficult to establish. On their haemodynamic effects, bradykinin acts during their acute administration, participating in their vasodilatation action, while during their chronic administration they act slightly or not at all. On their trophic effects, the action of the tissue kallikrein-kinin system, suggested by the results of animal experimentation, is yet to be demonstrated in man. For their effects on cardiovascular morbidity and mortality the role of bradykinin remains under discussion. Nevertheless, besides ACE inhibitors, the other therapeutic agents which increase the levels of bradykinin, such as neutral endopeptidase inhibitors, have a significant field of development in the course of cardiovascular pathologies.
Galinier
M
M
Fédération des services de cardiologie des hôpitaux, CHU de Rangueil, Toulouse 31403. galinier.m@chu-toulouse.fr
Pathak
A
A
Baixas
C
C
Alhabaj
S
S
Fallouh
V
V
Roncali
J
J
Schmutz
L
L
Massabuau
P
P
Fauvel
J M
JM
Bounhoure
J P
JP
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001920:Bradykinin / Q000494:pharmacology*; D002303:Cardiac Output, Low / Q000188:drug therapy*; D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects; D004195:Disease Models, Animal; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans
D000806:Angiotensin-Converting Enzyme Inhibitors; D001920:Bradykinin
Effets de la bradykinine dans les effets cardiovasculaires des inhibiteurs de l'enzyme de conversion.